GLAXO2018-04-012018-06-30in-bse-fin:OneOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares GLAXO 2018-04-01 2019-03-31 2018-06-26 INR Lakhs First quarter Single segment Pharmaceuticals 2018-04-01 2018-06-30 Unaudited Standalone 7356500000.00 177800000.00 7534300000.00 1784800000.00 1275500000.00 107100000.00 1259800000.00 2000000.00 113600000.00 1525600000.00 6068400000.00 1465900000.00 -82800000.00 1383100000.00 447000000.00 50200000.00 497200000.00 0.00 885900000.00 0.00 0.00 0.00 0.00 885900000.00 0.00 885900000.00 0.00 885900000.00 847000000.00 10 10.46 10.46 0.00 0.00 10.46 10.46 0.00 0.00 0.00 1. The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 24th July, 2018. n n2. Consequent to the introduction of Goods and Service Tax (GST) with effect from 1st July, 2017, Central Excise, Value Added Tax (VAT) etc. have been subsumed under GST. In accordance with Ind-AS115 on Revenue from Contracts with Customers and Schedule III of the Companies Act 2013, unlike Excise Duties, levies like GST, VAT etc. are not part of Revenue. Accordingly the figures for the quarter ended 30th June, 2018 are not comparable with the corresponding quarter. n n3. The figures for the preceding three months ended 31st March, 2018 are the balancing figures between the audited financial results for the year ended 31st March, 2018 and the year to date figures upto the third quarter for the nine months ended 31st December, 2017. n n4. Exceptional Items for the quarter ended 30th June, 2018 of Rs. 828 Lakhs, is a charge in establishment costs on account of restructuring of the commercial organisation to align with the future strategy of focused brand investment, supported by additional field force. Exceptional Items for the corresponding quarter ended 30th June, 2017 mainly relate to profit on sale of a property. n n5.The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made. n n6. In accordance with the requirements of Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out a limited review of the standalone financial results for the quarter ended 30th June, 2018. The standalone financial results for the three months ended 30th June, 2017, were reviewed by previous auditors Price Waterhouse & Co Bangalore LLP. n n7. Previous year/ periods figures have been re-grouped / re-classified wherever necessary. Other Expenses 1525600000.00